Provectus Biopharmaceuticals Management

Management Kriterienprüfungen 4/4

Provectus Biopharmaceuticals' CEO ist Ed Pershing , ernannt in Apr 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.75% der Aktien des Unternehmens, im Wert von $316.04K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.9 Jahre bzw. 5.1 Jahre.

Wichtige Informationen

Ed Pershing

Geschäftsführender

US$75.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.8%
Durchschnittliche Amtszeit des Managements	2.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.1yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Ed Pershing (71 yo)

less than a year

Amtszeit

US$75,000

Vergütung

Mr. Edward V. Pershing, also known as Ed, CPA has been Chairman of Provectus Biopharmaceuticals, Inc., since April 27, 2018 and serves as its Chief Executive Officer since April 2024. He served as the Chie...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Edward Pershing	CEO & Chairman of Board	less than a year	US$75.00k	0.75% $ 377.7k
Dominic Rodrigues	President & Vice Chairman of the Board	7.3yrs	US$75.00k	0.26% $ 128.7k
Eric Wachter	Co-Founder & CTO	12.3yrs	US$253.25k	1.58% $ 794.6k
Heather Raines	Chief Financial Officer	5.4yrs	US$125.00k	0.29% $ 145.0k

2.9yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: PVCTDas Führungsteam des Unternehmens gilt als erfahren (2.9 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Edward Pershing	CEO & Chairman of Board	6.3yrs	US$75.00k	0.75% $ 377.7k
Dominic Rodrigues	President & Vice Chairman of the Board	7.3yrs	US$75.00k	0.26% $ 128.7k
Frank Akers	Member of Strategic Advisory Board	5.1yrs	keine Daten	keine Daten
John Lacey	Chairman of Strategic Advisory Board & Independent Director	6.3yrs	US$80.00k	0.048% $ 23.9k
Harold Schmitz	Member of Scientific Advisory Board	4.9yrs	keine Daten	keine Daten
Webster Bailey	Independent Director	4.6yrs	US$80.00k	keine Daten
Aru Narendran	Member of Scientific Advisory Board	2.3yrs	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: PVCTDie Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).

Provectus Biopharmaceuticals Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

Recent updates

Provectus Biopharmaceuticals, Inc. announced a financing transaction

Provectus Biopharmaceuticals, Inc. Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer

Provectus Biopharmaceuticals, Inc. Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Advanced Cutaneous Melanoma

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy Pv-10 for Metastatic Uveal Melanoma

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10(R) and Keytruda(R) for First-Line Stage III Melanoma at Melanoma Bridge 2022

Provectus Biopharmaceuticals Presents Data from PV-10 Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology

Provectus Biopharmaceuticals, Inc., Annual General Meeting, Jun 22, 2022

Provectus Biopharmaceuticals Names Aru Narendran, MD, PhD to Scientific Advisory Board

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract for Oral Presentation at 2022 European Neuroendocrine Tumor Society (ENETS) Annual Conference

Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better

Provectus Biopharmaceuticals, Inc. Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research 2021 Congress

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10 at European Society for Medical Oncology (ESMO) Congress 2021

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Neuroendocrine Cancer Abstract At European Society for Medical Oncology (ESMO) Congress 2021

Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology 2021 Annual Meeting

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Provectus Biopharmaceuticals, Inc. Directs Funding in the Amount of $2.5 Million to Develop Animal Health Drug Products Through Partnerships with State Universities That Have Agriculture and Veterinary Medicine Programs and the Knoxville-Headquartered Biotechnology Company

Provectus Biopharmaceuticals Announces Acceptance of PV-10 Immunotherapy Abstracts at American Society of Clinical Oncology 2021 Annual Meeting

Provectus Biopharmaceuticals Announces Release of Preprint Manuscript Describing Preclinical Study of Pv-10® Immunotherapy and Chemotherapy for Treatment of Pancreatic Cancer

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

Provectus Biopharmaceuticals, Inc. Announces Acceptance of PV-10® Pancreatic Cancer Abstract at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Provectus Biopharmaceuticals, Inc. Highlights Stage Iv M1c Patient Outcome from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma At ESMO Virtual Congress 2020

Provectus Biopharmaceuticals, Inc. Announces Presentation of 2-Year Data from Combination Therapy Trial of PV-10 and KEYTRUDA for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter